在有风险的接受静脉钆贝葡胺增强肝脏MRI检查结果为阴性的患者中肝细胞癌的发生频率
本回顾性研究纳入204例需影像监测的肝细胞癌风险患者,评估多期钆贝葡胺增强MRI阴性后临床显著肝结节(LR-4、LR-5、LR-M)的发生率。中位随访35个月,总体结节累积发生率为10.5%,临床显著结节在9-15个月累积发生率为1.1%;作者认为阴性MRI后延长监测间隔可能合理,需进一步研究。
要点
- MRI阴性后12±3个月结节累积发生率为2.1%,含1个LR-4、1个LR-M和2个LR-3结节。
- 临床显著结节(LR-4、LR-5、LR-M)在9-15个月累积发生率为1.1%。
- 70%(143/204)患者至少行一次超声随访,索引阴性MRI后无患者超声随访阳性。
核心结论
- 在有风险的接受静脉钆贝葡胺增强肝脏MRI检查结果为阴性的患者中,第一年内临床显著肝结节发生率为1.1%。
- 作者认为,虽然高危患者仍需持续监测,但阴性MRI后延长监测间隔可能合理,需进一步研究探索这一可能性。
研究设计与样本
- 回顾性研究,纳入204例需影像监测的肝细胞癌风险患者(平均年龄58.9±10.2岁,128例女性),其中172例肝硬化。
- 索引检查为多期钆贝葡胺增强MRI且结果为阴性,随访为符合LI-RADS的多期CT或MRI至少12个月,或12个月内阳性随访。
- 随访检查分类为阴性(无结节或仅LR-1结节)或阳性(除LR-1外的结节),记录首次阳性检查时间、结节类型和结节累积发生率。
诊断标准与关键数值
- 基于CT/MRI随访(中位35个月,范围12-80个月),总体结节累积发生率为10.5%。
- 结节累积发生率在6-9个月为0.5%,在12±3个月为2.1%,包括1个LR-4结节、1个LR-M结节和2个LR-3结节。
- 临床显著结节累积发生率在9-15个月为1.1%。
- 70%(143/204)患者至少行一次超声随访,索引阴性MRI后无患者出现超声随访阳性。
临床应用与阅片要点
- 作者认为,高危患者仍需持续监测,但阴性MRI后延长监测间隔可能合理,需进一步研究探索这一可能性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the rate of development of clinically significant liver nodules (LR-4, LR-5, LR-M) after a negative MRI in an HCC screening population.
METHODS: This retrospective study included patients at risk of developing HCC requiring imaging surveillance who had undergone multiphase Gadobenate dimeglumine-enhanced MRI that was negative and had follow up LI-RADS compliant multiphase CTs or MRIs for at least 12 months or positive follow-up within 12 months. Follow-up examinations were classified as negative (no nodules or only LR-1 nodules) or positive (nodule other than LR-1). Time-to-first positive examination, types of nodules, and cumulative incidence of nodule development were recorded.
RESULTS: 204 patients (mean age 58.9 ± 10.2 years, 128 women), including 172 with cirrhosis, were included. Based CT/MRI follow-up (median 35 months, range 12-80 months), the overall cumulative incidence of developing a nodule was 10.5%. Cumulative incidence of nodule development was: 0.5% at 6-9 months and 2.1% at 12 ± 3 months, including one LR-4 nodule, one LR-M nodule, and two LR-3 nodules. The cumulative incidence of clinically significant nodule development was 1.1% at 9-15 months. 70% (143/204) of patients also underwent at least one US follow-up, and no patient developed a positive US examination following index negative MRI.
CONCLUSION: Clinically significant liver nodules develop in 1.1% of at-risk patients in the first year following negative MRI. While ongoing surveillance is necessary for at-risk patients, our study suggests than longer surveillance intervals after a negative MRI may be reasonable and that further research is needed to explore this possibility.
引用
- Zaki IH, Shropshire E, Zhang S, et al. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY). 2020. PMID: 32951065. doi:10.1007/s00261-020-02771-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。